65 filings
8-K
JNCE
Jounce Therapeutics Inc
4 May 23
Termination of a Material Definitive Agreement
7:22am
8-K
JNCE
Jounce Therapeutics Inc
30 Mar 23
Departure of Directors or Certain Officers
4:08pm
8-K
JNCE
Jounce Therapeutics Inc
27 Mar 23
Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights
9:02am
8-K
JNCE
Jounce Therapeutics Inc
15 Mar 23
Other Events
6:21am
8-K
JNCE
Jounce Therapeutics Inc
13 Mar 23
Regulation FD Disclosure
6:30am
8-K
xjtw8kzbryaszjxc9
23 Feb 23
Proposed acquisition of and merger with Redx Pharma Plc ("Target") – Deed of Irrevocable Undertaking
6:11am
8-K
x46kuw9eel96 t2mw
20 Jan 23
Departure of Directors or Certain Officers
8:07am
8-K
70y48jf21cfabz7ers2b
5 Jan 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:35pm
8-K
lux5zh ws
27 Dec 22
Entry into a Material Definitive Agreement
4:31pm
8-K
xh5t4tr1nz zaqadl2
20 Dec 22
Departure of Directors or Certain Officers
7:21am
8-K
1f2cvcd9
10 Nov 22
Jounce Therapeutics Reports Third Quarter 2022 Financial Results
7:17am
8-K
s5e05leatje owr
30 Aug 22
Regulation FD Disclosure
8:07am
8-K
g1eojqrjtvmxezdeu9a
4 Aug 22
Jounce Therapeutics Reports Second Quarter 2022 Financial Results
7:13am
8-K
guapj66 2qzl
27 Jun 22
Submission of Matters to a Vote of Security Holders
4:32pm
8-K
ptrx1mor5b6m5ct8z5
5 May 22
Jounce Therapeutics Reports First Quarter 2022 Financial Results
7:07am
8-K
n1k3ja
7 Mar 22
Regulation FD Disclosure
7:06am
8-K
68zpx4hf
2 Mar 22
Jounce Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
7:06am
8-K
top4mi gdpa3
10 Jan 22
Results of Operations and Financial Condition
7:31am
8-K
cji1y0tz634n
4 Nov 21
Entry into a Material Definitive Agreement
4:21pm
8-K
pibempdfwnnuhvk
4 Nov 21
Jounce Therapeutics Reports Third Quarter 2021 Financial Results
7:12am